Methods of treating cancer with Anti-ROR1 antibody drug conjugates
WO2026112136A3PCT designated stage Publication Date: 2026-07-23IMMUNOME INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- IMMUNOME INC
- Filing Date
- 2025-11-19
- Publication Date
- 2026-07-23
AI Technical Summary
Technical Problem
There is a need for improved and targeted therapies for ROR1, a transmembrane glycoprotein that is expressed at elevated levels in various malignant tumors, including CLL, breast cancer, ovarian cancer, and lung adenocarcinoma, as existing therapies are inadequate.
Method used
Development of anti-ROR1 antibody drug conjugates (ADCs) that deliver a topoisomerase I-inhibiting camptothecin payload to ROR1-expressing malignant cells, administered at specific dosages over a 21-day cycle, tailored to the subject's body weight.
Benefits of technology
The anti-ROR1 ADCs effectively reduce disease progression in ROR1-expressing cancers, including solid tumors and leukemias, as measured by clinical criteria, and are effective even in cases relapsed or refractory to other therapies.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025056100_23072026_PF_FP_ABST
Abstract
Provided herein are antibody drug conjugates for ROR1 for treating ROR1 expressing cancers.
Need to check novelty before this filing date? Find Prior Art